semaglutide nih A new clinical trial supported by the National Institutes of Health (NIH) found that a medication commonly used for weight loss, such as semaglutide, may also help reduce heavy drinking in individuals PDB-101: Diabetes Mellitus: Diabetes Mellitus:

The July 2026 Medicare bridge program will help (copay drops to $50/month), but for now, affordability is the elephant in thedenver Goal confusion shouldnt surprise us

Even though this has not been demonstrated with Wegovy in humans, the FDA warns against giving anyone with a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer) or a history of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) GLP-1 agonists like Wegovy

Semaglutide, initially approved to treat Type 2 diabetes under the brand name Ozempic, can be used to promote weight loss

GLP-1 may serve as an indicator of ongoing metabolic stress and unresolved catabolic state, both of which are linked to muscle wasting and the emergence of chronic critical illness after sepsis (53)

Always report suspected side effects through the Yellow Card Scheme (yellowcard.mhra.gov.uk) to contribute to ongoing medication safety surveillance

4.9 SURPASS-AP-combo trial: tirzepatide vs